Vosevi 沃士韦 (Sofosbuvir/Velpatasvir/Voxilaprevir) 400mg Tablets | GLT

Generic Information: Vosevi 沃士韦 (Sofosbuvir/Velpatasvir/Voxilaprevir Tablets) — Gilead China Version

Known in China as 沃士韦®, with the Chinese generic name 索磷维伏片, this product is the China-marketed presentation of Vosevi — Gilead Sciences' single-tablet combination of sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg. The pack supplied here is the Chinese original: 28 film-coated tablets per bottle with the Chinese labeling 沃士韦® Vosevi® 索磷维伏片, approved by the NMPA in December 2019 for the retreatment of chronic hepatitis C. It is worth understanding the naming structure clearly: 沃士韦 and Vosevi are the same brand and the same originator medicine from the same manufacturer — the Chinese name is simply the registered trade name used in mainland China, exactly as the identical tablet circulates internationally under the single Vosevi name. This page therefore covers the authentic Gilead product, not a generic copy, in its China-market packaging.

What Is Vosevi 沃士韦 Used For?

First-line DAA regimens cure the large majority of chronic hepatitis C patients, but a small yet clinically important group fails therapy — most often patients whose earlier regimen contained an NS5A inhibitor, and who therefore carry viruses with NS5A resistance substitutions. 沃士韦 exists precisely for this group: in China it is approved for adults with chronic HCV infection who previously received a DAA-containing regimen, without cirrhosis or with compensated cirrhosis (Child-Pugh A). In the pivotal POLARIS program conducted across genotypes 1-6, approximately 95%-97% of such previously treated patients reached SVR12 — virologic cure — after one 12-week course. For patients who were treated in the earlier interferon era or with first-generation DAAs and did not clear the virus, this tablet represents the most complete rescue option currently registered.

How Does Vosevi 沃士韦 Work?

Each film-coated tablet packs three antivirals that attack the hepatitis C virus at three separate stages. Sofosbuvir masquerades as a natural nucleotide and is incorporated by the virus's NS5B polymerase into the growing RNA strand, where it halts further copying. Velpatasvir paralyzes NS5A, the viral protein that organizes the replication complex, so newly made replication machinery cannot function. Voxilaprevir shuts down the NS3/4A protease that the virus needs to cut its own polyprotein into working enzymes. Because the three mechanisms are independent, resistance that developed against an earlier NS5A inhibitor does not neutralize the whole regimen — the added protease-inhibitor axis carried the concept of "pan-genotypic rescue" into routine practice, which is the principal reason this fourth-generation combination outperforms repeating an older two-drug course.

Indications

沃士韦 (Vosevi, sofosbuvir/velpatasvir/voxilaprevir tablets) is indicated in China for the treatment of adult chronic hepatitis C patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have previously been treated with a DAA-containing regimen — covering patients who failed a regimen including an NS5A inhibitor (genotypes 1-6) and patients with genotype 1a or 3 who failed a sofosbuvir-based regimen without an NS5A inhibitor. The same treatment-experienced population defines the reimbursement scope of the product within China's national medical insurance drug list, where it is included as a Category B (乙类) negotiated item.

Dosage

Take one tablet once daily with food for a fixed 12-week course; the combination of all three ingredients in a single tablet means there is nothing to adjust or combine by the patient. If a dose is missed and remembered on the same day, take it as soon as possible; never take two tablets to make up for a forgotten one. No dose adjustment is needed for renal impairment at any stage, including dialysis, or for mild liver impairment. The regimen must not be used in decompensated or severe hepatic impairment (Child-Pugh B/C), where exposure to voxilaprevir increases substantially and alternative regimens should be chosen by the treating physician.

Side Effects

Across the clinical program, treatment discontinuations for adverse events were rare (about 0.2% over 12 weeks). The most frequently reported reactions — each seen in at least one patient in ten — were headache, fatigue, diarrhea, and nausea, typically transient. The Chinese package insert carries a boxed-style warning that the tablet must not be combined with several everyday medicines: rosuvastatin and dabigatran are prohibited combinations, products containing ethinyl estradiol (many oral contraceptives) should be switched to alternatives, and amiodarone must be avoided because of life-threatening slow-heartbeat events reported with sofosbuvir combinations. Strong inducers such as rifampicin, carbamazepine, or St. John's wort can collapse velpatasvir exposure and are likewise contraindicated. Patients with past hepatitis B should be monitored for viral reactivation during and after therapy.

Storage

Store below 30°C, sealed in the original bottle away from moisture. Keep out of the reach of children, and use the tablets before the expiry date shown on the Chinese-language label.

Why Choose the GLT?

The China presentation of Vosevi is notable for its cost profile: following national insurance negotiation and inclusion as a Category B item in China's medical insurance list, the domestically supplied originator has become one of the most affordable presentations of this rescue therapy anywhere — typically 60%-80% below the U.S. list price per bottle. Through GLT, a Hong Kong-licensed supplier, both individual patients and institutional buyers can access authentic Gilead China packs with full batch documentation, alongside other market versions of the same tablet, and choose the presentation that best balances documentation requirements and budget. Every order is verified stock, never parallel-unverified product.

How to Order Vosevi 沃士韦 (Sofosbuvir/Velpatasvir/Voxilaprevir)

To order the China version of Vosevi (沃士韦® 索磷维伏片, 400 mg/100 mg/100 mg × 28 tablets), contact our team on WhatsApp at +86 15234153837 or by email at [email protected]. Let us know the quantity needed and the destination country, and we will confirm availability, documentation, and delivery arrangements.

FAQ

Is 沃士韦 the same drug as Vosevi? Yes. 沃士韦 is the registered Chinese trade name of the same Gilead originator tablet sold internationally as Vosevi — same three ingredients (sofosbuvir 400 mg, velpatasvir 100 mg, voxilaprevir 100 mg), same manufacturer, same once-daily tablet.

Is Vosevi reimbursed in China? It is included in China's national medical insurance drug list as a Category B negotiated item, with reimbursement limited to the approved treatment-experienced hepatitis C population; the listing has substantially lowered the domestic price relative to markets without such negotiation.

Who should take Vosevi instead of a two-drug regimen? Patients who already failed a prior DAA course — especially one containing an NS5A inhibitor — are the intended users; first-treatment patients are generally served by simpler regimens such as sofosbuvir/velpatasvir alone.

Which medicines must be avoided with this tablet? Amiodarone, rosuvastatin, dabigatran, ethinyl estradiol-containing products, and strong enzyme inducers (rifampicin, carbamazepine, phenobarbital, phenytoin, St. John's wort) are contraindicated or require regimen changes — always hand your doctor a complete list of current medications before starting.